Pictet Asset Management Ltd. increased its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 46.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,126,275 shares of the biopharmaceutical company’s stock after buying an additional 358,695 shares during the quarter. Pictet Asset Management Ltd. owned 0.50% of Alexion Pharmaceuticals worth $158,005,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the business. Commerzbank Aktiengesellschaft FI grew its position in shares of Alexion Pharmaceuticals by 151.5% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock worth $16,145,000 after buying an additional 79,943 shares during the last quarter. HPM Partners LLC grew its holdings in shares of Alexion Pharmaceuticals by 267.2% in the second quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock worth $656,000 after acquiring an additional 4,861 shares during the period. Principal Financial Group Inc. grew its holdings in Alexion Pharmaceuticals by 1.2% during the second quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock valued at $40,823,000 after purchasing an additional 4,115 shares during the period. Assenagon Asset Management S.A. grew its holdings in Alexion Pharmaceuticals by 4,509.0% during the third quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after purchasing an additional 864,967 shares during the period. Finally, Ameriprise Financial Inc. grew its holdings in Alexion Pharmaceuticals by 0.4% during the second quarter. Ameriprise Financial Inc. now owns 6,175,296 shares of the biopharmaceutical company’s stock valued at $751,363,000 after purchasing an additional 25,724 shares during the period. Hedge funds and other institutional investors own 96.71% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://weekherald.com/2017/11/14/alexion-pharmaceuticals-inc-alxn-shares-bought-by-pictet-asset-management-ltd.html.
In other news, EVP Julie O’neill sold 4,375 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total transaction of $636,300.00. Following the completion of the transaction, the executive vice president now directly owns 26,092 shares of the company’s stock, valued at approximately $3,794,820.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now directly owns 5,480 shares of the company’s stock, valued at $799,038.80. The disclosure for this sale can be found here. Insiders have sold 16,490 shares of company stock worth $2,337,251 over the last ninety days. 4.35% of the stock is currently owned by insiders.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down $1.72 during midday trading on Tuesday, reaching $113.45. 1,620,000 shares of the company were exchanged, compared to its average volume of 2,289,474. Alexion Pharmaceuticals, Inc. has a 1 year low of $96.18 and a 1 year high of $149.34. The firm has a market capitalization of $25,350.00, a price-to-earnings ratio of 23.55, a P/E/G ratio of 1.25 and a beta of 1.22. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. During the same quarter last year, the business earned $1.23 earnings per share. Alexion Pharmaceuticals’s revenue was up 7.5% compared to the same quarter last year. analysts anticipate that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current fiscal year.
ALXN has been the topic of several research analyst reports. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective on the stock in a research report on Tuesday, October 31st. Morgan Stanley reaffirmed an “overweight” rating and set a $153.00 target price (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. J P Morgan Chase & Co raised Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $163.00 to $175.00 in a research note on Tuesday, September 5th. Leerink Swann reiterated an “outperform” rating and set a $182.00 price objective (up previously from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. They noted that the move was a valuation call. Finally, Stifel Nicolaus decreased their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a report on Tuesday, October 24th. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $154.01.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.